Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines

R. D. Lin, W. C. Hou, K. Y. Yen, M. H. Lee

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Monoamine oxidase (MAO) catalyzes the oxidative deamination of biogenic amines accompaned by the release of H2O2. Two subtypes, MAO-A and MAO-B, exist on the basis of their specificities to substrates and inhibitors. The regulation of MAO-B activity is important in the treatment of neurodegenerative diseases. Twenty-seven species of plants used in traditional Chinese medicines, selected from an enthnobotanical survey, were used in an investigation of their inhibitory effect on MAO-B in rat brain homogenates. The 50% aqueous methanol extracts of four active extracts, Arisaema amurense, Lilium brownii var. colchesteri, Lycium chinense, and Uncaria rhynchophylla, exhibited the best activity and selectivity towards MAO-B with IC50 values of 0.44, 0.29, 0.40, and 0.03 mg/ml, respectively. A kinetic study of MAO-B inhibition by the four extracts using the Lineweaver-Burk plot for each active extract revealed the IC50 concentrations, and results show that: Ki = 0.59 mg/ml for A. amurense for the mixed-type mode, Ki = 0.58 mg/ml for L. brownii var. colchesteri for the mixed-type mode, Ki = 5.01 mg/ml for L. chinense for the uncompetitive mode, and Ki = 0.02 mg/ml for U. rhynchophylla for the uncompetitive mode. These may therefore be candidates for use in delaying the progressive degeneration caused by neurological diseases.

Original languageEnglish
Pages (from-to)650-656
Number of pages7
JournalPhytomedicine
Volume10
Issue number8
DOIs
Publication statusPublished - Nov 2003

Fingerprint

amine oxidase (flavin-containing)
Herbal Medicine
herbal medicines
Monoamine Oxidase
Uncaria rhynchophylla
Lycium chinense
Lycium
extracts
Inhibitory Concentration 50
Arisaema
inhibitory concentration 50
Uncaria
Lilium
Neurodegenerative diseases
deamination
Deamination
Biogenic Amines
biogenic amines
Chinese Traditional Medicine
neurodegenerative diseases

Keywords

  • Arisaema amurense
  • Lilium brownii var. colchesteri
  • Lycium chinense
  • Monoamine oxidase (MAO)
  • Uncaria rhynchophylla

ASJC Scopus subject areas

  • Plant Science
  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines. / Lin, R. D.; Hou, W. C.; Yen, K. Y.; Lee, M. H.

In: Phytomedicine, Vol. 10, No. 8, 11.2003, p. 650-656.

Research output: Contribution to journalArticle

@article{b5d2ee11fe674269abf976856b33bdb6,
title = "Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines",
abstract = "Monoamine oxidase (MAO) catalyzes the oxidative deamination of biogenic amines accompaned by the release of H2O2. Two subtypes, MAO-A and MAO-B, exist on the basis of their specificities to substrates and inhibitors. The regulation of MAO-B activity is important in the treatment of neurodegenerative diseases. Twenty-seven species of plants used in traditional Chinese medicines, selected from an enthnobotanical survey, were used in an investigation of their inhibitory effect on MAO-B in rat brain homogenates. The 50{\%} aqueous methanol extracts of four active extracts, Arisaema amurense, Lilium brownii var. colchesteri, Lycium chinense, and Uncaria rhynchophylla, exhibited the best activity and selectivity towards MAO-B with IC50 values of 0.44, 0.29, 0.40, and 0.03 mg/ml, respectively. A kinetic study of MAO-B inhibition by the four extracts using the Lineweaver-Burk plot for each active extract revealed the IC50 concentrations, and results show that: Ki = 0.59 mg/ml for A. amurense for the mixed-type mode, Ki = 0.58 mg/ml for L. brownii var. colchesteri for the mixed-type mode, Ki = 5.01 mg/ml for L. chinense for the uncompetitive mode, and Ki = 0.02 mg/ml for U. rhynchophylla for the uncompetitive mode. These may therefore be candidates for use in delaying the progressive degeneration caused by neurological diseases.",
keywords = "Arisaema amurense, Lilium brownii var. colchesteri, Lycium chinense, Monoamine oxidase (MAO), Uncaria rhynchophylla",
author = "Lin, {R. D.} and Hou, {W. C.} and Yen, {K. Y.} and Lee, {M. H.}",
year = "2003",
month = "11",
doi = "10.1078/0944-7113-00324",
language = "English",
volume = "10",
pages = "650--656",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",
number = "8",

}

TY - JOUR

T1 - Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines

AU - Lin, R. D.

AU - Hou, W. C.

AU - Yen, K. Y.

AU - Lee, M. H.

PY - 2003/11

Y1 - 2003/11

N2 - Monoamine oxidase (MAO) catalyzes the oxidative deamination of biogenic amines accompaned by the release of H2O2. Two subtypes, MAO-A and MAO-B, exist on the basis of their specificities to substrates and inhibitors. The regulation of MAO-B activity is important in the treatment of neurodegenerative diseases. Twenty-seven species of plants used in traditional Chinese medicines, selected from an enthnobotanical survey, were used in an investigation of their inhibitory effect on MAO-B in rat brain homogenates. The 50% aqueous methanol extracts of four active extracts, Arisaema amurense, Lilium brownii var. colchesteri, Lycium chinense, and Uncaria rhynchophylla, exhibited the best activity and selectivity towards MAO-B with IC50 values of 0.44, 0.29, 0.40, and 0.03 mg/ml, respectively. A kinetic study of MAO-B inhibition by the four extracts using the Lineweaver-Burk plot for each active extract revealed the IC50 concentrations, and results show that: Ki = 0.59 mg/ml for A. amurense for the mixed-type mode, Ki = 0.58 mg/ml for L. brownii var. colchesteri for the mixed-type mode, Ki = 5.01 mg/ml for L. chinense for the uncompetitive mode, and Ki = 0.02 mg/ml for U. rhynchophylla for the uncompetitive mode. These may therefore be candidates for use in delaying the progressive degeneration caused by neurological diseases.

AB - Monoamine oxidase (MAO) catalyzes the oxidative deamination of biogenic amines accompaned by the release of H2O2. Two subtypes, MAO-A and MAO-B, exist on the basis of their specificities to substrates and inhibitors. The regulation of MAO-B activity is important in the treatment of neurodegenerative diseases. Twenty-seven species of plants used in traditional Chinese medicines, selected from an enthnobotanical survey, were used in an investigation of their inhibitory effect on MAO-B in rat brain homogenates. The 50% aqueous methanol extracts of four active extracts, Arisaema amurense, Lilium brownii var. colchesteri, Lycium chinense, and Uncaria rhynchophylla, exhibited the best activity and selectivity towards MAO-B with IC50 values of 0.44, 0.29, 0.40, and 0.03 mg/ml, respectively. A kinetic study of MAO-B inhibition by the four extracts using the Lineweaver-Burk plot for each active extract revealed the IC50 concentrations, and results show that: Ki = 0.59 mg/ml for A. amurense for the mixed-type mode, Ki = 0.58 mg/ml for L. brownii var. colchesteri for the mixed-type mode, Ki = 5.01 mg/ml for L. chinense for the uncompetitive mode, and Ki = 0.02 mg/ml for U. rhynchophylla for the uncompetitive mode. These may therefore be candidates for use in delaying the progressive degeneration caused by neurological diseases.

KW - Arisaema amurense

KW - Lilium brownii var. colchesteri

KW - Lycium chinense

KW - Monoamine oxidase (MAO)

KW - Uncaria rhynchophylla

UR - http://www.scopus.com/inward/record.url?scp=0344197553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344197553&partnerID=8YFLogxK

U2 - 10.1078/0944-7113-00324

DO - 10.1078/0944-7113-00324

M3 - Article

C2 - 14692725

AN - SCOPUS:0344197553

VL - 10

SP - 650

EP - 656

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

IS - 8

ER -